<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01245933</url>
  </required_header>
  <id_info>
    <org_study_id>01GI0881</org_study_id>
    <nct_id>NCT01245933</nct_id>
  </id_info>
  <brief_title>Impact of Systemic Manifestations/Comorbidities on Clinical State, Prognosis, Utilisation of Health Care Resources in Patients With COPD</brief_title>
  <acronym>COSYCONET</acronym>
  <official_title>Impact of Systemic Manifestations/Comorbidities on Clinical State, Prognosis and Utilisation of Health Care Resources in Patients With COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philipps University Marburg Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Philipps University Marburg Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the prevalence and severity of extrapulmonary
      disorders and to quantify the impact of extrapulmonary organ manifestations on morbidity and
      mortality of COPD patients.

      Furthermore the investigators evaluate the relationship between systemic inflammation and
      organ involvement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic diseases and comorbidities have an increasing impact on individual life and health
      care use, as exemplified in chronic obstructive pulmonary disease (COPD). Currently,
      independent, comprehensive databases allowing for an integrated view are lacking. The study
      will for the first time establish a large, comprehensive longitudinal database covering a
      broad panel of comorbidities an markers of systemic alterations. These data will be of unique
      value in revealing specific phenotypes of COPD via patterns and risk profiles of
      comorbidities, enabling a more precise diagnosis and targeting of therapy, and an efficient
      allocation of resources.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in BODE-Score at 18 months</measure>
    <time_frame>at initial visite, after 18 month</time_frame>
    <description>The BODE-Score comprises BMI, airway obstruction, dyspnea and exercise capacity and is a good predictor for death in COPD patients. Progression is defined as a change in BODE-score by &gt;=1 point over the observation period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>COPD related mortality</measure>
    <time_frame>after 18 months</time_frame>
    <description>The rate of mortality was elevated after 6, 18, 36 and 54 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COPD related hospitalization</measure>
    <time_frame>after 18 months</time_frame>
    <description>The rate of hospitalizations was elevated in every visit.</description>
  </secondary_outcome>
  <enrollment type="Actual">2741</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood urine sputum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Since the original recruitment strategy was not as successful as expected,the mode of
        recruitment was extended to other physicians, patients' groups and organisations and
        advertising to local media. The recruitment is supported by professional measures of
        communication organized by the coordinating centre Marburg.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged 40 years and older

          -  diagnosis of COPD (GOLD-Criteria) or chronic bronchitis

          -  informed consent

          -  available for repeated study visits pver 18 months

        Exclusion Criteria:

          -  having undergone big lung surgery (e.g. lung reduction, lung transplant)

          -  Moderate or severe exacerbation within the last 4 weeks

          -  having a lung tumor

          -  Unable to walk or to understand the intention of the project
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claus Vogelmeier, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Philipps University Marburg Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ev. Lungenklinik (ELK), Krankenhausbetriebs gGmbH, Pneumologische Klinik</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forschungszentrum Borstel, Medizinische Klinik</name>
      <address>
        <city>Borstel</city>
        <zip>23845</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Donaustauf, Zentrum für Pneumologie</name>
      <address>
        <city>Donaustauf</city>
        <zip>93093</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruhrlandklinik Essen, Westdeutsches Lungenzentrum</name>
      <address>
        <city>Essen</city>
        <zip>45239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EvA-Study Center, Helholtz Zentrum München</name>
      <address>
        <city>Gauting</city>
        <zip>82131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Justus-Liebig-Universität, Medizinische Klinik II</name>
      <address>
        <city>Gießen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Greifswald der Ernst-Moritz-Arndt Universität, Zentrum für Innere Medizin</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Großhansdorf, Pneumologisches Forschungsinstitut</name>
      <address>
        <city>Großhansdorf</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HIT-Hamburger Institut für Therapieforschung GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical School Hannover, Dep. of Pneumology</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Saarland</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fachklinik für Lungenerkrankungen Philippsstiftung ev.</name>
      <address>
        <city>Immenhausen</city>
        <zip>34376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitiy of Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig, Department Innere Medizin</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philipps-University Marburg, Medical Center, Dep. of Pneumology</name>
      <address>
        <city>Marburg</city>
        <zip>35042</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ludwig-Maximilians-University, Medizinische Klinik Innenstadt</name>
      <address>
        <city>Munic</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg, Medizinische Klinik 3, Schwerpunkt Pneumologie, Allergologie und Schlafmedizin</name>
      <address>
        <city>Nürnberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Rostock, Zentrum für Innere Medizin, Abt. f. Pneumologie</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Berchtesgardener Land, Schön Kliniken, Fachzentrum für Pneumologie, Allergologie und Schlafmedizin</name>
      <address>
        <city>Schönau am Königssee</city>
        <zip>83471</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Bethanien gGmbH</name>
      <address>
        <city>Solingen</city>
        <zip>42699</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Missionsärztliche Klinik GmbH, Innere Medizin</name>
      <address>
        <city>Würzburg</city>
        <zip>97067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.asconet.net</url>
    <description>Description of the study, study results, links to relevant organisaton</description>
  </link>
  <reference>
    <citation>Jörres RA, Welte T, Bals R, Koch A, Schnoor M, Vogelmeier C. [Systemic manifestations and comorbidities in patients with chronic obstructive pulmonary disease (COPD) and their effect on clinical state and course of the disease--an overview of the cohort study COSYCONET]. Dtsch Med Wochenschr. 2010 Mar;135(10):446-9. doi: 10.1055/s-0030-1249185. Epub 2010 Mar 2. German.</citation>
    <PMID>20198540</PMID>
  </reference>
  <results_reference>
    <citation>Wacker ME, Jörres RA, Schulz H, Heinrich J, Karrasch S, Karch A, Koch A, Peters A, Leidl R, Vogelmeier C, Holle R; COSYCONET-Consortium. Direct and indirect costs of COPD and its comorbidities: Results from the German COSYCONET study. Respir Med. 2016 Feb;111:39-46. doi: 10.1016/j.rmed.2015.12.001. Epub 2015 Dec 10.</citation>
    <PMID>26725462</PMID>
  </results_reference>
  <results_reference>
    <citation>Karch A, Vogelmeier C, Welte T, Bals R, Kauczor HU, Biederer J, Heinrich J, Schulz H, Gläser S, Holle R, Watz H, Korn S, Adaskina N, Biertz F, Vogel C, Vestbo J, Wouters EF, Rabe KF, Söhler S, Koch A, Jörres RA; COSYCONET Study Group. The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline. Respir Med. 2016 May;114:27-37. doi: 10.1016/j.rmed.2016.03.008. Epub 2016 Mar 11.</citation>
    <PMID>27109808</PMID>
  </results_reference>
  <results_reference>
    <citation>Wacker ME, Jörres RA, Karch A, Wilke S, Heinrich J, Karrasch S, Koch A, Schulz H, Watz H, Leidl R, Vogelmeier C, Holle R; COSYCONET-Consortium. Assessing health-related quality of life in COPD: comparing generic and disease-specific instruments with focus on comorbidities. BMC Pulm Med. 2016 May 10;16(1):70. doi: 10.1186/s12890-016-0238-9.</citation>
    <PMID>27160582</PMID>
  </results_reference>
  <results_reference>
    <citation>Wacker ME, Jörres RA, Karch A, Koch A, Heinrich J, Karrasch S, Schulz H, Peters A, Gläser S, Ewert R, Baumeister SE, Vogelmeier C, Leidl R, Holle R; COSYCONET study group. Relative impact of COPD and comorbidities on generic health-related quality of life: a pooled analysis of the COSYCONET patient cohort and control subjects from the KORA and SHIP studies. Respir Res. 2016 Jul 12;17(1):81. doi: 10.1186/s12931-016-0401-0.</citation>
    <PMID>27405652</PMID>
  </results_reference>
  <results_reference>
    <citation>Lucke T, Herrera R, Wacker M, Holle R, Biertz F, Nowak D, Huber RM, Söhler S, Vogelmeier C, Ficker JH, Mückter H, Jörres RA; COSYCONET-Consortium. Systematic Analysis of Self-Reported Comorbidities in Large Cohort Studies - A Novel Stepwise Approach by Evaluation of Medication. PLoS One. 2016 Oct 28;11(10):e0163408. doi: 10.1371/journal.pone.0163408. eCollection 2016.</citation>
    <PMID>27792735</PMID>
  </results_reference>
  <results_reference>
    <citation>Alter P, Watz H, Kahnert K, Pfeifer M, Randerath WJ, Andreas S, Waschki B, Kleibrink BE, Welte T, Bals R, Schulz H, Biertz F, Young D, Vogelmeier CF, Jörres RA. Airway obstruction and lung hyperinflation in COPD are linked to an impaired left ventricular diastolic filling. Respir Med. 2018 Apr;137:14-22. doi: 10.1016/j.rmed.2018.02.011. Epub 2018 Feb 19.</citation>
    <PMID>29605197</PMID>
  </results_reference>
  <results_reference>
    <citation>Kahnert K, Lucke T, Huber RM, Behr J, Biertz F, Vogt A, Watz H, Alter P, Fähndrich S, Bals R, Holle R, Karrasch S, Söhler S, Wacker M, Ficker JH, Parhofer KG, Vogelmeier C, Jörres RA; COSYCONET consortium. Relationship of hyperlipidemia to comorbidities and lung function in COPD: Results of the COSYCONET cohort. PLoS One. 2017 May 15;12(5):e0177501. doi: 10.1371/journal.pone.0177501. eCollection 2017.</citation>
    <PMID>28505167</PMID>
  </results_reference>
  <results_reference>
    <citation>Fähndrich S, Biertz F, Karch A, Kleibrink B, Koch A, Teschler H, Welte T, Kauczor HU, Janciauskiene S, Jörres RA, Greulich T, Vogelmeier CF, Bals R; COSYCONET investigators. Cardiovascular risk in patients with alpha-1-antitrypsin deficiency. Respir Res. 2017 Sep 15;18(1):171. doi: 10.1186/s12931-017-0655-1.</citation>
    <PMID>28915894</PMID>
  </results_reference>
  <results_reference>
    <citation>Kahnert K, Alter P, Young D, Lucke T, Heinrich J, Huber RM, Behr J, Wacker M, Biertz F, Watz H, Bals R, Welte T, Wirtz H, Herth F, Vestbo J, Wouters EF, Vogelmeier CF, Jörres RA. The revised GOLD 2017 COPD categorization in relation to comorbidities. Respir Med. 2018 Jan;134:79-85. doi: 10.1016/j.rmed.2017.12.003. Epub 2017 Dec 5.</citation>
    <PMID>29413512</PMID>
  </results_reference>
  <results_reference>
    <citation>Kahnert K, Lucke T, Biertz F, Lechner A, Watz H, Alter P, Bals R, Behr J, Holle R, Huber RM, Karrasch S, Stubbe B, Wacker M, Söhler S, Wouters EF, Vogelmeier C, Jörres RA; COSYCONET study group. Transfer factor for carbon monoxide in patients with COPD and diabetes: results from the German COSYCONET cohort. Respir Res. 2017 Jan 13;18(1):14. doi: 10.1186/s12931-016-0499-0.</citation>
    <PMID>28086884</PMID>
  </results_reference>
  <results_reference>
    <citation>Houben-Wilke S, Jörres RA, Bals R, Franssen FM, Gläser S, Holle R, Karch A, Koch A, Magnussen H, Obst A, Schulz H, Spruit MA, Wacker ME, Welte T, Wouters EF, Vogelmeier C, Watz H. Peripheral Artery Disease and Its Clinical Relevance in Patients with Chronic Obstructive Pulmonary Disease in the COPD and Systemic Consequences-Comorbidities Network Study. Am J Respir Crit Care Med. 2017 Jan 15;195(2):189-197. doi: 10.1164/rccm.201602-0354OC.</citation>
    <PMID>27532739</PMID>
  </results_reference>
  <results_reference>
    <citation>Karl FM, Holle R, Bals R, Greulich T, Jörres RA, Karch A, Koch A, Karrasch S, Leidl R, Schulz H, Vogelmeier C, Wacker ME; COSYCONET Study Group. Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients. Respir Res. 2017 Apr 17;18(1):60. doi: 10.1186/s12931-017-0543-8.</citation>
    <PMID>28416015</PMID>
  </results_reference>
  <results_reference>
    <citation>Smid DE, Franssen FME, Gonik M, Miravitlles M, Casanova C, Cosio BG, de Lucas-Ramos P, Marin JM, Martinez C, Mir I, Soriano JB, de Torres JP, Agusti A, Atalay NB, Billington J, Boutou AK, Brighenti-Zogg S, Chaplin E, Coster S, Dodd JW, Dürr S, Fernandez-Villar A, Groenen MTJ, Guimarães M, Hejduk K, Higgins V, Hopkinson NS, Horita N, Houben-Wilke S, Janssen DJA, Jehn M, Joerres R, Karch A, Kelly JL, Kim YI, Kimura H, Koblizek V, Kocks JH, Kon SSC, Kwon N, Ladeira I, Lee SD, Leuppi JD, Locantore N, Lopez-Campos JL, D-C Man W, Maricic L, Mendoza L, Miedinger D, Mihaltan F, Minami S, van der Molen T, Murrells TJ, Nakken N, Nishijima Y, Norman IJ, Novotna B, O'Donnell DE, Ogata Y, Pereira ED, Piercy J, Price D, Pothirat C, Raghavan N, Ringbaek T, Sajkov D, Sigari N, Singh S, Small M, da Silva GF, Tanner RJ, Tsiligianni IG, Tulek B, Tzanakis N, Vanfleteren LEGW, Watz H, Webb KA, Wouters EFM, Xie GG, Yoshikawa M, Spruit MA. Redefining Cut-Points for High Symptom Burden of the Global Initiative for Chronic Obstructive Lung Disease Classification in 18,577 Patients With Chronic Obstructive Pulmonary Disease. J Am Med Dir Assoc. 2017 Dec 1;18(12):1097.e11-1097.e24. doi: 10.1016/j.jamda.2017.09.003. Review.</citation>
    <PMID>29169740</PMID>
  </results_reference>
  <results_reference>
    <citation>Wacker ME, Kitzing K, Jörres RA, Leidl R, Schulz H, Karrasch S, Karch A, Koch A, Vogelmeier CF, Holle R. The contribution of symptoms and comorbidities to the economic impact of COPD: an analysis of the German COSYCONET cohort. Int J Chron Obstruct Pulmon Dis. 2017 Dec 4;12:3437-3448. doi: 10.2147/COPD.S141852. eCollection 2017.</citation>
    <PMID>29270005</PMID>
  </results_reference>
  <results_reference>
    <citation>Alter P, Jörres RA, Watz H, Welte T, Gläser S, Schulz H, Bals R, Karch A, Wouters EFM, Vestbo J, Young D, Vogelmeier CF. Left ventricular volume and wall stress are linked to lung function impairment in COPD. Int J Cardiol. 2018 Jun 15;261:172-178. doi: 10.1016/j.ijcard.2018.02.074.</citation>
    <PMID>29657040</PMID>
  </results_reference>
  <results_reference>
    <citation>Alter P, Rabe KF, Schulz H, Vogelmeier CF, Jörres RA. Influence of body mass on predicted values of static hyperinflation in COPD. Int J Chron Obstruct Pulmon Dis. 2018 Aug 23;13:2551-2555. doi: 10.2147/COPD.S164096. eCollection 2018.</citation>
    <PMID>30197511</PMID>
  </results_reference>
  <results_reference>
    <citation>Alter P, Jörres RA. Concomitance of cardiovascular and pulmonary disorders: mutual bystanders or causal interactions? Kardiol Pol. 2018;76(7):1027-1028. doi: 10.5603/KP.2018.0132.</citation>
    <PMID>29984808</PMID>
  </results_reference>
  <results_reference>
    <citation>Graf J, Lucke T, Herrera R, Watz H, Holle R, Vogelmeier C, Ficker JH, Jörres RA. Compatibility of medication with PRISCUS criteria and identification of drug interactions in a large cohort of patients with COPD. Pulm Pharmacol Ther. 2018 Apr;49:123-129. doi: 10.1016/j.pupt.2018.01.011. Epub 2018 Feb 5.</citation>
    <PMID>29421666</PMID>
  </results_reference>
  <results_reference>
    <citation>Graf J, Jörres RA, Lucke T, Nowak D, Vogelmeier CF, Ficker JH. Medical Treatment of COPD. Dtsch Arztebl Int. 2018 Sep 14;155(37):599-605. doi: 10.3238/arztebl.2018.0599.</citation>
    <PMID>30282573</PMID>
  </results_reference>
  <results_reference>
    <citation>Greulich T, Mager S, Lucke T, Koczulla AR, Bals R, Fähndrich S, Jörres RA, Alter P, Kirsten A, Vogelmeier CF, Watz H. Longitudinal stability of blood eosinophil count strata in the COPD COSYCONET cohort. Int J Chron Obstruct Pulmon Dis. 2018 Sep 28;13:2999-3002. doi: 10.2147/COPD.S165909. eCollection 2018.</citation>
    <PMID>30319247</PMID>
  </results_reference>
  <results_reference>
    <citation>Kahnert K, Alter P, Welte T, Huber RM, Behr J, Biertz F, Watz H, Bals R, Vogelmeier CF, Jörres RA. Uric acid, lung function, physical capacity and exacerbation frequency in patients with COPD: a multi-dimensional approach. Respir Res. 2018 Jun 4;19(1):110. doi: 10.1186/s12931-018-0815-y.</citation>
    <PMID>29866121</PMID>
  </results_reference>
  <results_reference>
    <citation>Kahnert K, Jobst B, Biertz F, Biederer J, Watz H, Huber RM, Behr J, Grenier PA, Alter P, Vogelmeier CF, Kauczor HU, Jörres RA. Relationship of spirometric, body plethysmographic, and diffusing capacity parameters to emphysema scores derived from CT scans. Chron Respir Dis. 2019 Jan-Dec;16:1479972318775423. doi: 10.1177/1479972318775423. Epub 2018 May 9.</citation>
    <PMID>29742906</PMID>
  </results_reference>
  <results_reference>
    <citation>Kaireit TF, Voskrebenzev A, Gutberlet M, Freise J, Jobst B, Kauczor HU, Welte T, Wacker F, Vogel-Claussen J. Comparison of quantitative regional perfusion-weighted phase resolved functional lung (PREFUL) MRI with dynamic gadolinium-enhanced regional pulmonary perfusion MRI in COPD patients. J Magn Reson Imaging. 2019 Apr;49(4):1122-1132. doi: 10.1002/jmri.26342. Epub 2018 Oct 22.</citation>
    <PMID>30350440</PMID>
  </results_reference>
  <results_reference>
    <citation>Keller A, Fehlmann T, Ludwig N, Kahraman M, Laufer T, Backes C, Vogelmeier C, Diener C, Biertz F, Herr C, Jörres RA, Lenhof HP, Meese E, Bals R; COSYCONET Study Group. Genome-wide MicroRNA Expression Profiles in COPD: Early Predictors for Cancer Development. Genomics Proteomics Bioinformatics. 2018 Jun;16(3):162-171. doi: 10.1016/j.gpb.2018.06.001. Epub 2018 Jul 5.</citation>
    <PMID>29981854</PMID>
  </results_reference>
  <results_reference>
    <citation>Triphan SMF, Biederer J, Burmester K, Fellhauer I, Vogelmeier CF, Jörres RA, Kauczor HU, Heußel CP, Wielpütz MO, Jobst BJ. Design and application of an MR reference phantom for multicentre lung imaging trials. PLoS One. 2018 Jul 5;13(7):e0199148. doi: 10.1371/journal.pone.0199148. eCollection 2018.</citation>
    <PMID>29975714</PMID>
  </results_reference>
  <results_reference>
    <citation>Alter P, Watz H, Kahnert K, Rabe KF, Biertz F, Fischer R, Jung P, Graf J, Bals R, Vogelmeier CF, Jörres RA. Effects of airway obstruction and hyperinflation on electrocardiographic axes in COPD. Respir Res. 2019 Mar 27;20(1):61. doi: 10.1186/s12931-019-1025-y.</citation>
    <PMID>30917825</PMID>
  </results_reference>
  <results_reference>
    <citation>Byng D, Lutter JI, Wacker ME, Jörres RA, Liu X, Karrasch S, Schulz H, Vogelmeier C, Holle R. Determinants of healthcare utilization and costs in COPD patients: first longitudinal results from the German COPD cohort COSYCONET. Int J Chron Obstruct Pulmon Dis. 2019 Jul 5;14:1423-1439. doi: 10.2147/COPD.S201899. eCollection 2019.</citation>
    <PMID>31308648</PMID>
  </results_reference>
  <results_reference>
    <citation>Trudzinski FC, Kahnert K, Vogelmeier CF, Alter P, Seiler F, Fähndrich S, Watz H, Welte T, Speer T, Zewinger S, Biertz F, Kauczor HU, Jörres RA, Bals R; COSYCONET consortium. Combined effects of lung function, blood gases and kidney function on the exacerbation risk in stable COPD: Results from the COSYCONET cohort. Respir Med. 2019 Jul - Aug;154:18-26. doi: 10.1016/j.rmed.2019.06.007. Epub 2019 Jun 11.</citation>
    <PMID>31203096</PMID>
  </results_reference>
  <results_reference>
    <citation>Trudzinski FC, Alqudrah M, Omlor A, Zewinger S, Fliser D, Speer T, Seiler F, Biertz F, Koch A, Vogelmeier C, Welte T, Watz H, Waschki B, Fähndrich S, Jörres R, Bals R; German COSYCONET consortium. Consequences of chronic kidney disease in chronic obstructive pulmonary disease. Respir Res. 2019 Jul 12;20(1):151. doi: 10.1186/s12931-019-1107-x.</citation>
    <PMID>31299972</PMID>
  </results_reference>
  <results_reference>
    <citation>von Siemens SM, Jörres RA, Behr J, Alter P, Lutter J, Lucke T, Söhler S, Welte T, Watz H, Vogelmeier CF, Trudzinski F, Rief W, Herbig B, Kahnert K; COSYCONET study group. Effect of COPD severity and comorbidities on the result of the PHQ-9 tool for the diagnosis of depression: results from the COSYCONET cohort study. Respir Res. 2019 Feb 11;20(1):30. doi: 10.1186/s12931-019-0997-y.</citation>
    <PMID>30744630</PMID>
  </results_reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>November 18, 2010</study_first_submitted>
  <study_first_submitted_qc>November 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2010</study_first_posted>
  <last_update_submitted>August 27, 2019</last_update_submitted>
  <last_update_submitted_qc>August 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Philipps University Marburg Medical Center</investigator_affiliation>
    <investigator_full_name>Claus Vogelmeier</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>register</keyword>
  <keyword>comorbidities</keyword>
  <keyword>systemic inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <study_docs>
    <study_doc>
      <doc_type>general information</doc_type>
      <doc_url>http://www.asconet.net</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

